Accendra Health, Inc. (ACH)
| Market Cap | 216.73M -59.5% |
| Revenue (ttm) | 2.72B -0.0% |
| Net Income | -1.08B |
| EPS | -14.11 |
| Shares Out | 76.58M |
| PE Ratio | n/a |
| Forward PE | 5.68 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 617,400 |
| Open | 2.690 |
| Previous Close | 2.710 |
| Day's Range | 2.690 - 3.000 |
| 52-Week Range | 1.840 - 9.550 |
| Beta | 1.70 |
| Analysts | Hold |
| Price Target | 4.49 (+58.66%) |
| Earnings Date | May 11, 2026 |
About ACH
Accendra Health, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States. It offers a range of products and services for in-home care and delivery for diabetes treatment; home respiratory therapy, including home oxygen and non-invasive ventilation services; obstructive sleep apnea treatment, such as continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services. The company also supplies other home medical equipment, patient care product lines includi... [Read more]
Financial Performance
In 2025, Accendra Health's revenue was $2.76 billion, an increase of 3.06% compared to the previous year's $2.68 billion. Losses were -$1.10 billion, 203.5% more than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for ACH stock is "Hold." The 12-month stock price target is $4.49, which is an increase of 58.66% from the latest price.
News
Accendra Health Announces Offers and Consent Solicitations
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) today announced that it has commenced an offer to exchange (the “Exchange Offers”) any and all of the Company's outsta...
Accendra Health Transcript: AGM 2026
The meeting approved all four proposals, including director elections and incentive plan. The company highlighted its transition to a pure play home-based care provider, serving most of the U.S. with a streamlined workforce and strong brand presence.
Accendra Health price target raised to $4.50 from $3 at UBS
UBS raised the firm’s price target on Accendra Health (ACH) to $4.50 from $3 and keeps a Neutral rating on the shares.
Accendra Health price target raised to $6 from $5 at Baird
Baird raised the firm’s price target on Accendra Health (ACH) to $6 from $5 and keeps an Outperform rating on the shares.
Accendra Health price target raised to $5 from $3.25 at Citi
Citi raised the firm’s price target on Accendra Health (ACH) to $5 from $3.25 and keeps a Buy rating on the shares.
Accendra Health Earnings Call Transcript: Q1 2026
First quarter 2026 results met expectations, with revenue down 6.8% year-over-year but up 1% excluding a major payer exit. Gross margins nearly doubled post-divestiture, and a comprehensive balance sheet optimization will reduce debt and extend maturities.
Accendra Health Earnings release: Q1 2026
Accendra Health released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Accendra Health Slides: Q1 2026
Accendra Health has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 11, 2026.
Accendra Health Quarterly report: Q1 2026
Accendra Health has published its Q1 2026 quarterly earnings report on May 11, 2026.
Accendra Health reports Q1 EPS (4c) vs. 29c last year
Reports Q1 revenue $627.8M vs. $673.9M last year. “Our first quarter results were aligned with our expectations as we continue our transformation into a pure play home based care company.
Accendra Health backs FY26 guidance for net revenue and adjusted EBITDA
06:38 EDT Accendra Health (ACH) backs FY26 guidance for net revenue and adjusted EBITDA
Accendra Health Reports First Quarter 2026 Financial Results and Announces Comprehensive Balance Sheet Optimization Transaction
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) today reported financial results for the first quarter ended March 31, 2026, and announced a more than $1.5 billion comprehensive bala...
Accendra Health Announces First Quarter 2026 Earnings Release Date and Conference Call
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) plans to release financial results for the first quarter of 2026 on Monday, May 11, 2026, before trading begins on the...
Accendra Health Proxy statement: Proxy filing
Accendra Health filed a proxy statement on April 2, 2026, providing details for shareholder voting and corporate governance matters.
Accendra Health Proxy statement: Proxy filing
Accendra Health filed a proxy statement on April 2, 2026, providing details for shareholder voting and corporate governance matters.
Accendra Health price target lowered to $3.25 from $4 at Citi
Citi lowered the firm’s price target on Accendra Health (ACH) to $3.25 from $4 and keeps a Buy rating on the shares.
Accendra Health price target lowered to $3 from $4 at UBS
UBS analyst Kevin Caliendo lowered the firm’s price target on Accendra Health (ACH) to $3 from $4 and keeps a Buy rating on the shares. The firm updated the company’s…
Accendra Health Earnings Call Transcript: Q4 2025
Revenue grew over 3% in 2025 to nearly $2.8B, with strong performance in sleep, ostomy, and urology. 2026 guidance reflects a $300M revenue headwind from a major payer loss, but cost reductions and technology investments are expected to support margins and cash flow.
Accendra Health Annual report: Q4 2025
Accendra Health has published its Q4 2025 annual report on February 19, 2026.
Accendra Health Earnings release: Q4 2025
Accendra Health released its Q4 2025 earnings on February 19, 2026, summarizing the period's financial results.
Accendra Health Slides: Q4 2025
Accendra Health has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 19, 2026.
Accendra Health Annual report: Q4 2025
Accendra Health has published its Q4 2025 annual report on February 19, 2026.
Accendra Health reports Q4 adjusted EPS 21c, consensus 22c
Reports Q4 revenue $709M, consensus $714.73M. “We ended the fourth quarter with the completion of the sale of the Products & Healthcare Services (P&HS) business on December 31, 2025, and…
Accendra Health sees FY26 revenue $2.55B-$2.65B, consensus $2.6B
Sees FY26 adjusted EBITDA $335M-$355M.
Accendra Health Reports Fourth Quarter 2025 Financial Results
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) today reported financial results for the fourth quarter ended December 31, 2025. Unless otherwise noted, the results herein reflect th...